文献速递外周动脉疾病

外周动脉疾病血管内血运重建后单药与双联抗血小板治疗的早期经济学评价

Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2025-07-24

该研究采用微观模拟模型,从医疗保健视角估算外周动脉疾病患者血管内血运重建后双联抗血小板治疗(DAPT,氯吡格雷联合低剂量阿司匹林)与单药抗血小板治疗(SAPT,氯吡格雷)的增量成本和质量调整生命年。

要点

  • DAPT年药费66欧元高于SAPT的47欧元,但事件减少可抵消药费差额。
  • 若DAPT减少缺血事件1%,即使增加大出血也占优SAPT。

核心结论

  • 在假定概率下,DAPT在外周动脉疾病血管内血运重建后患者中占优SAPT。
  • DAPT可能降低医疗成本并提高生活质量。

研究设计与样本

  • 采用微观模拟模型,从医疗保健视角估算增量成本和QALY,时间跨度為终生。
  • 模型输入来自文献和专家意见,并进行了阈值、确定性、概率性、敏感性和信息价值分析。

主要发现

  • DAPT年药费66欧元,SAPT年药费47欧元。
  • SAPT和DAPT总QALY分别为5.42和5.51。
  • 若DAPT减少缺血事件1%,即使增加大出血,DAPT仍占优SAPT。
  • 在假定DAPT大出血概率下,SAPT患者大出血概率降低从未超过DAPT患者任何心血管和肢体不良事件减少的正面效应。

临床怎么用

  • 对于外周动脉疾病血管内血运重建后患者,DAPT可能具有成本效益优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Health economic evaluations are performed in addition to clinical trials to inform decision-making. An early health economic evaluation was conducted to determine the potential cost-effectiveness of dual antiplatelet therapy (DAPT; clopidogrel and low-dose acetylsalicylic acid) versus single antiplatelet therapy (SAPT; clopidogrel) after endovascular revascularization in patients with peripheral artery disease (PAD). METHODS: A microsimulation model was developed to estimate incremental costs and quality-adjusted life-years with a lifetime time horizon from a health care perspective. Input for the model was found in literature and based on expert opinion. Threshold, deterministic, probabilistic, sensitivity, and value-of-information analyses were performed. RESULTS: Medication costs of DAPT (€66 yearly) compared to SAPT (€47 yearly) were compensated by a decrease in events. Total costs per patient were estimated at €80 469 and €76 925 (difference -€3 544) and total quality-adjusted life-years 5.42 and 5.51, for SAPT and DAPT respectively. At the assumed probabilities, if DAPT reduces ischemic events by 1%, DAPT will dominate SAPT in patients with PAD after endovascular revascularization even if it increases major bleeding. CONCLUSION: This early economic evaluation shows that DAPT will dominate SAPT in patients with PAD after endovascular revascularization at a small decrease in major adverse cardiovascular events and major adverse limb events. At the assumed DAPT probability for major bleeding, a decrease in probability of major bleeding in SAPT patients never outweighs the positive effect of any decrease of major adverse cardiovascular events and major adverse limb events for DAPT patients. DAPT could reduce health care costs and increase quality of life in patients with PAD.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Generaal MI, Wegerif ECJ, Ünlü Ç, et al. Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease. Ann Vasc Surg. 2025. PMID: 40714182. doi:10.1016/j.avsg.2025.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。